Cholecystokinjn Tetrapeptide: a Provocation Agent for Research in Panic Disorder?
Panic disorder represents a significant psychiatric illness in the general population and is associated with a number of distressing and disabling complications (Marks, 1987). The core symptom of panic disorder is the repeated occurrence of panic attacks. These attacks are characterized by discrete episodes of intense anxiety or fear accompanied by somatic, cognitive and behavioural symptoms. When panic disorder is associated with extensive phobic avoidance and impairment of overall functioning a diagnosis of panic disorder with agoraphobia is made.
Unable to display preview. Download preview PDF.
- Beinfeld, M. C. (1988). Cholecystokinin and gastrin chemistry, distribution, release, and activity. In Negro-Vilan, A. and Conn, P. M. (eds.), Peptide Hormones: Effects and Mechanisms of Action, vol. II, CRC Press, Boca Raton, Ha, 41–77.Google Scholar
- Bradwejn, J., Koszycki, D., Meterissian, G. and Shriqui, C. (1989). Cholecystokinin panic: patient control differences. New Research Program and Abstracts, 142nd Meeting of American Psychiatric Association, San Francisco, NR 334, p. 183.Google Scholar
- Gorman, J. M., Fyer, M. R., Liebowitz, M. R. and Klein, D. F. (1987). In Meltzer, H. Y. (ed.), Psychopharmacology: The Third Generation of Progress, Raven, New York, 985–93.Google Scholar
- Karkanias, C. D., Block, G. A., Reines, S. and Bradwejn, J. (1989). Neurobiology of panic disorder. Letter, Am. J. Psychiatry, 146, 1357.Google Scholar
- Redmond, D. E. Jr (1987). Studies of the nucleus locus coeruleus in monkeys and hypothesis for neuropsychopharmacology. In Meltzer, H. Y. (ed.), Psychopharmacology: The Third Generation of Progress, Raven, New York.Google Scholar